Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy

ABSTRACT: This is a Phase I study to evaluate the safety and tolerability of sacituzumab govitecan in combination with capecitabine for advanced gastrointestinal cancers after progression on standard therapy, and to assess correlation of outcomes with the biomarker Trop-2.

DISEASE(S): Gastrointestinal Neoplasms,Colorectal Cancer,Gastric Cancer,Gastrointestinal Cancer,Esophageal Cancer,Pancreatic Cancer

PROVIDER: 107815 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR